499 related articles for article (PubMed ID: 32998963)
1. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.
Huarte E; O'Connor RS; Peel MT; Nunez-Cruz S; Leferovich J; Juvekar A; Yang YO; Truong L; Huang T; Naim A; Milone MC; Smith PA
Clin Cancer Res; 2020 Dec; 26(23):6299-6309. PubMed ID: 32998963
[TBL] [Abstract][Full Text] [Related]
2. Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases.
Covington M; He X; Scuron M; Li J; Collins R; Juvekar A; Shin N; Favata M; Gallagher K; Sarah S; Xue CB; Peel M; Burke K; Oliver J; Fay B; Yao W; Huang T; Scherle P; Diamond S; Newton R; Zhang Y; Smith P
Eur J Pharmacol; 2020 Oct; 885():173505. PubMed ID: 32861662
[TBL] [Abstract][Full Text] [Related]
3. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
[No Abstract] [Full Text] [Related]
4. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
Li J; Wu Z; Zhao N
Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
[TBL] [Abstract][Full Text] [Related]
5. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.
Zi FM; Ye LL; Zheng JF; Cheng J; Wang QM
Medicine (Baltimore); 2021 May; 100(19):e25786. PubMed ID: 34106613
[TBL] [Abstract][Full Text] [Related]
6. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Sterner RM; Sakemura R; Cox MJ; Yang N; Khadka RH; Forsman CL; Hansen MJ; Jin F; Ayasoufi K; Hefazi M; Schick KJ; Walters DK; Ahmed O; Chappell D; Sahmoud T; Durrant C; Nevala WK; Patnaik MM; Pease LR; Hedin KE; Kay NE; Johnson AJ; Kenderian SS
Blood; 2019 Feb; 133(7):697-709. PubMed ID: 30463995
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells.
Xu N; Yang XF; Xue SL; Tan JW; Li MH; Ye J; Lou XY; Yu Z; Kang LQ; Yan ZQ; Yu L; Chen SN; Wang YT
Biochem Biophys Res Commun; 2022 Mar; 595():54-61. PubMed ID: 35101664
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced leukemia in mice with mRNA engineered T cells.
Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy.
Read JA; Rouce RH; Mo F; Mamonkin M; King KY
Transplant Cell Ther; 2023 Mar; 29(3):165.e1-165.e7. PubMed ID: 36592718
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy.
Pan J; Deng B; Ling Z; Song W; Xu J; Duan J; Wang Z; Chang AH; Feng X; Tan Y
J Cell Mol Med; 2021 Jan; 25(2):1089-1099. PubMed ID: 33314568
[TBL] [Abstract][Full Text] [Related]
11. Management of cytokine release syndrome related to CAR-T cell therapy.
Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
[TBL] [Abstract][Full Text] [Related]
12. Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo.
Su YL; Wang X; Mann M; Adamus TP; Wang D; Moreira DF; Zhang Z; Ouyang C; He X; Zhang B; Swiderski PM; Forman SJ; Baltimore D; Li L; Marcucci G; Boldin MP; Kortylewski M
Blood; 2020 Jan; 135(3):167-180. PubMed ID: 31805184
[TBL] [Abstract][Full Text] [Related]
13. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
[TBL] [Abstract][Full Text] [Related]
14. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
Chou CK; Turtle CJ
Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
[No Abstract] [Full Text] [Related]
15. Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome.
Zheng N; Long Y; Bai Z; Li J; Wang H; Song DD; Liu HL; Shi JH; Zhao S
J Transl Med; 2024 Jan; 22(1):58. PubMed ID: 38221609
[TBL] [Abstract][Full Text] [Related]
16. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
[TBL] [Abstract][Full Text] [Related]
17. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome.
Wei Y; Li C; Bian H; Qian W; Jin K; Xu T; Guo X; Lu X; Su F
Mol Cancer; 2021 Jan; 20(1):5. PubMed ID: 33397398
[TBL] [Abstract][Full Text] [Related]
18. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
[TBL] [Abstract][Full Text] [Related]
19. Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.
Aldoss I; Khaled SK; Budde E; Stein AS
Curr Oncol Rep; 2019 Jan; 21(1):4. PubMed ID: 30666425
[TBL] [Abstract][Full Text] [Related]
20. A major role for CD4
Boulch M; Cazaux M; Cuffel A; Ruggiu M; Allain V; Corre B; Loe-Mie Y; Hosten B; Cisternino S; Auvity S; Thieblemont C; Caillat-Zucman S; Bousso P
Cell Rep Med; 2023 Sep; 4(9):101161. PubMed ID: 37595589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
